Literature DB >> 11294920

Familial cerebellar ataxia with muscle coenzyme Q10 deficiency.

O Musumeci1, A Naini, A E Slonim, N Skavin, G L Hadjigeorgiou, N Krawiecki, B M Weissman, C Y Tsao, J R Mendell, S Shanske, D C De Vivo, M Hirano, S DiMauro.   

Abstract

OBJECTIVE: To describe a clinical syndrome of cerebellar ataxia associated with muscle coenzyme Q10 (CoQ10) deficiency.
BACKGROUND: Muscle CoQ10 deficiency has been reported only in a few patients with a mitochondrial encephalomyopathy characterized by 1) recurrent myoglobinuria; 2) brain involvement (seizures, ataxia, mental retardation), and 3) ragged-red fibers and lipid storage in the muscle biopsy.
METHODS: Having found decreased CoQ10 levels in muscle from a patient with unclassified familial cerebellar ataxia, the authors measured CoQ10 in muscle biopsies from other patients in whom cerebellar ataxia could not be attributed to known genetic causes.
RESULTS: The authors found muscle CoQ10 deficiency (26 to 35% of normal) in six patients with cerebellar ataxia, pyramidal signs, and seizures. All six patients responded to CoQ10 supplementation; strength increased, ataxia improved, and seizures became less frequent.
CONCLUSIONS: Primary CoQ10 deficiency is a potentially important cause of familial ataxia and should be considered in the differential diagnosis of this condition because CoQ10 administration seems to improve the clinical picture.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11294920     DOI: 10.1212/wnl.56.7.849

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  59 in total

1.  Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.

Authors:  Padmaja Yerramilli-Rao; M Flint Beal; Dai Watanabe; Karl Kieburtz; Elisabeth A de Blieck; Mitsuaki Kitano; Kazunori Hosoe; Iwao Funahashi; Merit E Cudkowicz
Journal:  Int J Toxicol       Date:  2012-01-20       Impact factor: 2.032

Review 2.  CoQ(10) deficiencies and MNGIE: two treatable mitochondrial disorders.

Authors:  Michio Hirano; Caterina Garone; Catarina M Quinzii
Journal:  Biochim Biophys Acta       Date:  2012-01-18

Review 3.  Role of mitochondria in multiple sclerosis.

Authors:  Bernadette Kalman
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

4.  A history of mitochondrial diseases.

Authors:  Salvatore Dimauro
Journal:  J Inherit Metab Dis       Date:  2010-05-21       Impact factor: 4.982

5.  Why are there no proven therapies for genetic mitochondrial diseases?

Authors:  Peter W Stacpoole
Journal:  Mitochondrion       Date:  2011-05-13       Impact factor: 4.160

6.  176th ENMC International Workshop: diagnosis and treatment of coenzyme Q₁₀ deficiency.

Authors:  Shamima Rahman; Catherine F Clarke; Michio Hirano
Journal:  Neuromuscul Disord       Date:  2011-07-01       Impact factor: 4.296

7.  Lack of aprataxin impairs mitochondrial functions via downregulation of the APE1/NRF1/NRF2 pathway.

Authors:  Beatriz Garcia-Diaz; Emanuele Barca; Andrea Balreira; Luis C Lopez; Saba Tadesse; Sindhu Krishna; Ali Naini; Caterina Mariotti; Barbara Castellotti; Catarina M Quinzii
Journal:  Hum Mol Genet       Date:  2015-05-14       Impact factor: 6.150

8.  Design and implementation of the first randomized controlled trial of coenzyme CoQ₁₀ in children with primary mitochondrial diseases.

Authors:  Peter W Stacpoole; Ton J deGrauw; Annette S Feigenbaum; Charles Hoppel; Douglas S Kerr; Shawn E McCandless; Michael V Miles; Brian H Robinson; Peter H Tang
Journal:  Mitochondrion       Date:  2012-09-25       Impact factor: 4.160

9.  Clinical presentations of coenzyme q10 deficiency syndrome.

Authors:  Catarina M Quinzii; Valentina Emmanuele; Michio Hirano
Journal:  Mol Syndromol       Date:  2014-07

10.  Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects.

Authors:  Luis C López; Catarina M Quinzii; Estela Area; Ali Naini; Shamima Rahman; Markus Schuelke; Leonardo Salviati; Salvatore Dimauro; Michio Hirano
Journal:  PLoS One       Date:  2010-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.